Elizabeth Macguidwin in Fort Myers, Florida

Medical School: Sorry, her university is not listed
Graduation Year: 2014
The Primary Medical Specialty for Elizabeth Macguidwin is listed as: Internal Medicine
Approximate Years of Experience: 10
PAC (PECOS ID)#: 8426275728
NPI #: 1811302011
NPI Created On: 06/25/2014
NPI Last Updated Listed as: 03/29/2021
Primary Taxonomy Code: 207R00000X
License Number:
5315067012
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• Humana
• Blue Cross Blue Shield
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Automated urinalysis test
2. Vaccine for influenza for injection into muscle
3. Pneumococcal vaccine for injection into muscle
4. Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage
5. Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older
6. Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle
7. New patient office or other outpatient visit, typically 45 minutes
8. Established patient office or other outpatient visit, typically 15 minutes
9. Established patient office or other outpatient, visit typically 25 minutes
10. Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes
11. Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge
12. Administration of influenza virus vaccine
13. Administration of pneumococcal vaccine
14. Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment
15. Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report
16. Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
17. Injection, denosumab, 1 mg